Hyperfine, Inc. (HYPR)
0.8133
-0.02
(-2.83%)
USD |
NASDAQ |
Sep 04, 16:00
0.8299
+0.02
(+2.04%)
After-Hours: 20:00
Hyperfine Research and Development Expense (Quarterly) : 3.865M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.865M |
| March 31, 2026 | 3.845M |
| December 31, 2025 | 3.825M |
| September 30, 2025 | 4.048M |
| June 30, 2025 | 4.541M |
| March 31, 2025 | 5.037M |
| December 31, 2024 | 5.105M |
| September 30, 2024 | 5.865M |
| June 30, 2024 | 5.959M |
| March 31, 2024 | 5.57M |
| December 31, 2023 | 5.962M |
| September 30, 2023 | 5.739M |
| Date | Value |
|---|---|
| June 30, 2023 | 5.331M |
| March 31, 2023 | 5.461M |
| December 31, 2022 | 5.219M |
| September 30, 2022 | 7.338M |
| June 30, 2022 | 7.265M |
| March 31, 2022 | 8.334M |
| December 31, 2021 | 8.893M |
| September 30, 2021 | 6.438M |
| June 30, 2021 | 6.037M |
| March 31, 2021 | 4.474M |
| December 31, 2020 | 3.551M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Abbott Laboratories | 892.00M |
| AngioDynamics, Inc. | 8.178M |
| Alphatec Holdings, Inc. | 18.17M |
| AtriCure, Inc. | 25.67M |
| Baxter International, Inc. | 125.00M |